Condition
Adult-Onset Still´s Disease
Total Trials
4
Recruiting
0
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (2)
P 3 (1)
Trial Status
Completed1
Withdrawn1
Terminated1
Active Not Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07151157Not ApplicableActive Not RecruitingPrimary
Therapeutic Value of Sirolimus in Refractory Adult-Onset Still's Disease
NCT05432960Phase 3WithdrawnPrimary
Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)
NCT02204293Phase 2TerminatedPrimary
Canakinumab for Treatment of Adult-onset Still's Disease
NCT01033656Phase 2CompletedPrimary
Treatment of Refractory Adult-onset Still's Disease With Anakinra: a Randomized Study
Showing all 4 trials